RT Journal Article
SR Electronic
T1 Clinical characteristics and outcomes of inpatients with neurological disease and COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.28.20082735
DO 10.1101/2020.04.28.20082735
A1 Benussi, Alberto
A1 Pilotto, Andrea
A1 Premi, Enrico
A1 Libri, Ilenia
A1 Giunta, Marcello
A1 Agosti, Chiara
A1 Alberici, Antonella
A1 Baldelli, Enrico
A1 Benini, Matteo
A1 Bonacina, Sonia
A1 Brambilla, Laura
A1 Caratozzolo, Salvatore
A1 Cortinovis, Matteo
A1 Costa, Angelo
A1 Piccinelli, Stefano Cotti
A1 Cottini, Elisabetta
A1 Cristillo, Viviana
A1 Delrio, Ilenia
A1 Filosto, Massimiliano
A1 Gamba, Massimo
A1 Gazzina, Stefano
A1 Gilberti, Nicola
A1 Gipponi, Stefano
A1 Imarisio, Alberto
A1 Invernizzi, Paolo
A1 Leggio, Ugo
A1 Leonardi, Matilde
A1 Liberini, Paolo
A1 Locatelli, Martina
A1 Masciocchi, Stefano
A1 Poli, Loris
A1 Rao, Renata
A1 Risi, Barbara
A1 Rozzini, Luca
A1 Scalvini, Andrea
A1 di Cola, Francesca Schiano
A1 Spezi, Raffaella
A1 Vergani, Veronica
A1 Volonghi, Irene
A1 Zoppi, Nicola
A1 Borroni, Barbara
A1 Magoni, Mauro
A1 Pezzini, Alessandro
A1 Padovani, Alessandro
YR 2020
UL http://medrxiv.org/content/early/2020/05/05/2020.04.28.20082735.abstract
AB Objective To report the clinical and laboratory characteristics, as well as treatment and clinical outcomes of patients admitted for neurological diseases with and without COVID-19.Methods In this retrospective, single center cohort study, we included all adult inpatients with confirmed COVID-19, admitted to a Neuro-COVID Unit from February 21, 2020, who had been discharged or died by April 5, 2020. Demographic, clinical, treatment, and laboratory data were extracted from medical records and compared (FDR-corrected) to those of neurological patients without COVID-19 admitted in the same period.Results 173 patients were included in this study, of whom 56 were positive for COVID-19 while 117 were negative for COVID-19. Patients with COVID-19 were older, had a different distribution regarding admission diagnoses, including cerebrovascular disorders, and had a higher quick Sequential Organ Failure Assessment (qSOFA) score on admission (all p<0.05). In-hospital mortality rates and incident delirium were significantly higher in the COVID-19 group (all p<0.005). COVID-19 and non-COVID patients with stroke had similar baseline characteristics but patients with COVID-19 had higher modified Rankin scale scores at discharge, with a significantly lower number of patients with a good outcome (all p<0.001).In patients with COVID-19, multivariable regressions showed increasing odds of in-hospital death associated with higher qSOFA scores (odds ratio 4.47, 95% CI 1.21-16.5; p=0.025), lower platelet count (0.98, 0.97-0.99; p=0.005) and higher lactate dehydrogenase (1.01, 1.00-1.03; p=0.009) on admission.Conclusions COVID-19 patients admitted with neurological disease, including stroke, have a significantly higher in-hospital mortality, incident delirium and higher disability than patients without COVID-19.Competing Interest StatementA. Benussi, A. Pilotto, E. Premi, I. Libri, M. Giunta, C. Agosti, A. Alberici, E. Baldelli, M. Benini, S. Bonacina, L. Brambilla, S. Caratozzolo, M. Cortinovis, A. Costa, S. Cotti Piccinelli, E. Cottini, V. Cristillo, I. Delrio, M. Gamba, S. Gazzina, N. Gilberti, S. Gipponi, A. Imarisio, P. Invernizzi, U. Leggio, M. Leonardi, P. Liberini, M. Locatelli, S. Masciocchi, L. Poli, R. Rao, B. Risi, L. Rozzini, A. Scalvini, F. Schiano di Cola, R. Spezi, V. Vergani, I. Volonghi, N. Zoppi, B. Borroni, M. Magoni, A. Pezzini report no disclosures relevant to the manuscript. A. Padovani is consultant and served on the scientific advisory board of GE Healthcare, Eli-Lilly and Actelion Ltd Pharmaceuticals, received speaker honoraria from Nutricia, PIAM, Lansgstone Technology, GE Healthcare, Lilly, UCB Pharma and Chiesi Pharmaceuticals.Funding StatementNo external funding was received.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll study data, including raw and analysed data, and materials will be available from the corresponding author, A.P., upon reasonable request.